STAT+: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more

The content discusses various updates within the pharmaceutical industry, including Congress abandoning reform efforts on pharmacy middlemen, the success of an obesity medication in a Phase 2 clinical study, and ongoing battles between drug makers and pharmacy benefit managers. Despite the gray skies, the article emphasizes the importance of embracing each day like a gift and offers maple bourbon as a stimulating choice to kickstart the day. The decision by Congress is seen as a missed opportunity for bipartisan healthcare reform. The success of the obesity medication from Viking Therapeutics adds to the competition in the obesity drug market.

Source link

error: Content is protected !!